TY - JOUR
T1 - Progress in molecularly targeted therapies for acute myeloid leukemia
AU - Tomita, Akihiro
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Genetic abnormalities including specific point mutations have recently been confirmed by applying comprehensive genome sequencing analyses. Molecular targeting therapies, which focus on the mutated proteins and over-expressed proteins in acute myeloid leukemia (AML) cells, are now being developed in clinical studies and/or based on in vitro analyses. This manuscript summarizes the genetic abnormalities in AML cells and some of the current molecular targeting therapies including FLT3 inhibitors (e.g. AC220; Quizartinib), Polo like kinase 1 (PLK1) inhibitors (e.g. BI-6727; Volasertib), IDH2 inhibitors (e.g. AG-221), and XPO1 inhibitors (e.g. KPT-330; Selinexor).
AB - Genetic abnormalities including specific point mutations have recently been confirmed by applying comprehensive genome sequencing analyses. Molecular targeting therapies, which focus on the mutated proteins and over-expressed proteins in acute myeloid leukemia (AML) cells, are now being developed in clinical studies and/or based on in vitro analyses. This manuscript summarizes the genetic abnormalities in AML cells and some of the current molecular targeting therapies including FLT3 inhibitors (e.g. AC220; Quizartinib), Polo like kinase 1 (PLK1) inhibitors (e.g. BI-6727; Volasertib), IDH2 inhibitors (e.g. AG-221), and XPO1 inhibitors (e.g. KPT-330; Selinexor).
UR - http://www.scopus.com/inward/record.url?scp=84942508664&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942508664&partnerID=8YFLogxK
U2 - 10.11406/rinketsu.56.130
DO - 10.11406/rinketsu.56.130
M3 - Article
C2 - 25765792
AN - SCOPUS:84942508664
SN - 0485-1439
VL - 56
SP - 130
EP - 138
JO - [Rinshō ketsueki] The Japanese journal of clinical hematology
JF - [Rinshō ketsueki] The Japanese journal of clinical hematology
IS - 2
ER -